Bank of New York Mellon Corp Has $892,000 Holdings in Sera Prognostics, Inc. (NASDAQ:SERA)

Bank of New York Mellon Corp grew its holdings in Sera Prognostics, Inc. (NASDAQ:SERA) by 100.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 150,708 shares of the company’s stock after acquiring an additional 75,441 shares during the quarter. Bank of New York Mellon Corp owned 0.46% of Sera Prognostics worth $892,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SERA. StepStone Group LP bought a new stake in Sera Prognostics in the 4th quarter valued at $61,000. Sanders Morris Harris LLC lifted its stake in shares of Sera Prognostics by 82.2% in the second quarter. Sanders Morris Harris LLC now owns 34,800 shares of the company’s stock valued at $206,000 after buying an additional 15,700 shares during the period. Twelve Points Wealth Management LLC bought a new stake in shares of Sera Prognostics in the second quarter valued at about $257,000. AWM Investment Company Inc. grew its position in Sera Prognostics by 56.0% during the first quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock worth $5,320,000 after buying an additional 209,762 shares in the last quarter. Finally, RA Capital Management L.P. bought a new position in Sera Prognostics during the first quarter valued at about $18,420,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Trading Down 5.1 %

Shares of SERA stock opened at $7.40 on Friday. Sera Prognostics, Inc. has a 12 month low of $1.56 and a 12 month high of $12.35. The company has a market capitalization of $241.64 million, a P/E ratio of -6.92 and a beta of 1.03. The stock has a 50 day moving average of $7.51 and a two-hundred day moving average of $8.24.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.08 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 11,843.79%. During the same period last year, the business earned ($0.34) earnings per share. Sell-side analysts predict that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Transactions at Sera Prognostics

In related news, insider John J. Boniface sold 5,022 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $37,263.24. Following the sale, the insider now owns 129,847 shares of the company’s stock, valued at $963,464.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Sera Prognostics news, CEO Zhenya Lindgardt sold 25,085 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $7.57, for a total transaction of $189,893.45. Following the completion of the transaction, the chief executive officer now directly owns 831,833 shares in the company, valued at $6,296,975.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John J. Boniface sold 5,022 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total transaction of $37,263.24. Following the completion of the sale, the insider now owns 129,847 shares in the company, valued at approximately $963,464.74. The disclosure for this sale can be found here. In the last three months, insiders sold 54,447 shares of company stock valued at $408,493. Company insiders own 15.80% of the company’s stock.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.